Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 20Leukemia, Myeloid, Acute 8Recurrence 7Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Thymoma 2Ovarian Neoplasms 2Carcinoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Richter's Transformation 1Rhabdoid Tumor 1Prostatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Melanoma 1MDS 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1

Interventions

selinexor 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × MDS × selinexor × Clear all
NCT06664970 2024-10-30

A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Peking Union Medical College Hospital

Phase 2 Enrolling by invitation
39 enrolled

MDS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡